Alvotech Targets MENA In Multi-Biosimilar Commercialization Deal

The Three Partners Are Based Across Europe And North Africa

 
• By Rosalind Rei

Three firms across Europe and North Africa sign to sell Alvotech biosimilar candidates in 19 MENA countries as the Icelandic developer shifts focus from R&D to global commercialization.

Satellite image of MENA region at night showing light from urban areas
Alvotech continues to cultivate commercial partnerships in the MENA region • Source: Shutterstock

Dubai-based Bioventure, Cairo-based Minapharm, and Berlin-based MiGenTra have signed a multi-product commercialization deal with Alvotech.

The three firms will share responsibilities to file, launch, and commercialize a portfolio of Alvotech biosimilar candidates in 19 countries in Africa and the Middle East (MENA) once

More from Biosimilars

More from Products